SCHEMBL26134649

SCHEMBL26134649

Oc1cc(/C=N/Nc2ncccn2)cc(O)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.46
▸ GAA P10253 9/20 0.46
▸ MEN1 O00255 4/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ POLB P06746 3/20 0.46
▸ RAB9A P51151 9/20 0.45
▸ NPC1 O15118 5/20 0.45
▸ HTT P42858 2/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ PKM P14618 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ KDM4E B2RXH2 6/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ LMNA P02545 5/20 0.41
▸ USP2 O75604 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26135334 1.00 MAPT (0.46) MAPTGAAMEN1KMT2APOLB
SCHEMBL26134653 1.00 MAPT (0.46) MAPTGAAMEN1KMT2APOLB
SCHEMBL28170025 0.74 RAB9A (0.68) MAPTGAAMEN1KMT2ARAB9A
SCHEMBL28170026 0.74 RAB9A (0.68) MAPTGAAMEN1KMT2ARAB9A
SCHEMBL28170028 0.70 KMT2A (0.63) MAPTGAAMEN1KMT2ARAB9A
SCHEMBL28170029 0.70 KMT2A (0.63) MAPTGAAMEN1KMT2ARAB9A
SCHEMBL17560863 0.70 SMN1; SMN2 (0.47) MAPTGAAMEN1KMT2APOLB
SCHEMBL28170611 0.70 LMNA (0.51) MAPTGAAMEN1KMT2APOLB
SCHEMBL17560859 0.70 SMN1; SMN2 (0.47) MAPTGAAMEN1KMT2APOLB
SCHEMBL26134880 0.68 LMNA (0.47) MAPTGAAMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214982-A1 COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2025-07-03 — — US disclosed
EP-4499615-A1 COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY Ramot at Tel-Aviv University Ltd. (IL) 2025-02-05 — — EP disclosed
WO-2023187783-A1 COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2023-10-05 — — WO disclosed
WO-2023187783-A1 COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2023-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214982-A1 COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY ATF4, ERN1, ERN2 MAPT 2461/4885GAA 494/4885MEN1 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback